Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

EUCLIDS: Investigating the immune response to vaccination against Men B in infants

The Oxford Vaccine Group is currently looking to enrol healthy Caucasian children aged 8 to 12 weeks to a study of how children’s immune system responds to the new meningococcal B (MenB) vaccine and to what extent this is affected by different genes. All children enrolled in the study would receive, in addition to their routine immunisations, an immunisation course against meningococcal B, which is not currently available to children in the UK.

We intend to see which genes are important for making a good response to the Men B vaccine by looking at what genes are ‘switched on’ and ‘switched off’ after vaccination. We would also look to see whether the genes that are associated with side effects such as fever are the same ones that are needed for the vaccine to generate a good immune response. This information will help in the design of vaccines that are more effective and have fewer side effects in the future.

The study is open for healthy children aged 8 to 12 weeks, of Caucasian origin, who are yet to receive their vaccinations. The study will consist of 8 to 11 visits over an 11 month period, during which time your child would have 3 doses of the Men B vaccine in addition to their routine vaccines. They would also have 6 blood tests and 2 throat swabs. All study visits would be conducted at your home at a time convenient to you.

For further information on participating in the study, visit the study page.

 

Similar stories

Angelman syndrome: first patient to receive potential therapy in Oxford

Things that seemed impossible, only a few years ago, are happening today. The first patient in Europe and one of the first in the world was injected with a potential treatment, GTX-102, in a phase I/II clinical trial in Oxford.

New model for infant leukaemia announced

The breakthrough could lead to development of new treatments for infant Acute Lymphoblastic Leukaemia.

Why it's so hard to treat pain in infants

For decades physicians believed that premature babies didn’t experience pain. Here’s what doctors know now – and the innovative solutions being embraced by today's caregivers.

Oxford to work with Brazil to establish clinical research hub

The University of Oxford and Brazilian Ministry of Health have announced a joint initiative to set up a global health and clinical research unit in Brazil led by Professor Sue Ann Clemens CBE.

New atlas revealed of bone marrow haematopoiesis during development

A new study published this week in Nature, provides the most detailed analysis so far of the prenatal development of blood and immune cells in the bone marrow.

Promising discovery for treatment of neuromuscular diseases

Research led by Carlo Rinaldi and Catheryn Lim discovered that a naturally-occurring isoform of an androgen receptor can be used in therapy for spinal and bulbar muscular atrophy, and shows potential for other diseases.